Inactive Instrument

ONCODESIGN Stock price

Equities

ALONC

FR0011766229

Biotechnology & Medical Research

Dynamic Chart
Oncodesign Société Anonyme(ENXTPA:ALONC) dropped from Next Biotech Index CI
Oncodesign Services Names Successors as Chairman/CEO Departs MT
Oncodesign Services Shareholders Sell Majority Stake to Edmond de Rothschild Fund MT
Oncodesign Precision Medicine to List Directly on Euronext Access + Paris MT
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme. CI
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme. CI
Oncodesign Unit Gains Approval To List On Euronext Access + In Paris MT
Oncodesign Société Anonyme agreed to Spin-Off Oncodesign Precision Medicine. CI
Oncodesign Société Anonyme Announces Planned Separation of Its Two Business Areas CI
Oncodesign Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Sengine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors CI
Oncodesign Société Anonyme Reports Turnover Results for the Year Ended December 31, 2021 CI
Oncodesign Société Anonyme's Equity Buyback announced on February 15, 2021, has expired. CI
Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bowel Disease CI
Oncodesign : Appoints Chief Development Officer MT
More news
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 17-12-31
Chief Tech/Sci/R&D Officer - 19-12-31
Members of the board TitleAgeSince
Director/Board Member 75 14-02-02
62 -
Director/Board Member 55 08-05-13
More insiders
ONCODESIGN specializes in preclinical pharmacological evaluation services of new cancer therapies on behalf of the pharmaceutical and biotechnological companies. The group also provides research and development of drugs and biomarkers primarily for the treatment of cancer. The group's activity is organized around 3 business units: - Service: discovery, identification and selection of new therapeutic targets in oncology; - Biotech: development of a portfolio of therapeutic and diagnostic projects alone or through partnerships; - Artificial Intelligence: development of a platform for selecting new therapeutic targets in oncology. 60.3% of sales are abroad.
More about the company
  1. Stock
  2. Equities
  3. Stock ONCODESIGN - Euronext Paris